login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
India’s First H1N1 Drug Launched by Cipla
The generic version of the drug by Cipla named as Oseltamivir to treat Influenza A is expected to be priced at Rs 475 for 10 capsules. Also, in the offing, 75 ml syrup bottle is expected to be launched shortly that would be priced in the same fashion.
Dr J A Gogtay, Medical Director of Cipla has mentioned that based on WHO statement influenza being a benign ailment accounts for 2.5-5 lakhs of deaths across the globe annually. These deaths comprise chiefly of elderly individuals or those with underlying conditions of heart, kidneys, lungs etc. In this year 2009, the patterns in fatal-deaths have been unexpectedly high with H1N1 virus attacking healthy individuals too.
Like any other H1N1 product, Antiflu will be sold under Schedule X category in India. Dr Gogtay has added that the drug would be dispensed strictly under physician’s prescription and would be made available in the market only to the chemists possessing the license to sell drugs under Schedule X category. Ranbaxy Laboratories, Strides Arcolab and Hetero Drugs are the other three laboratories from India that are approved to manufacture Oseltamivir apart from Cipla. In the process to tackle this epidemic, Cipla has already supplied to the government of India with nearly 2 million capsules.
Dr Gogtay hastens to conclude that there are only three to four manufacturers of Oseltamivir in India. However, Antiflu is the only medicament that seems to have qualified by WHO for tackling Swine flu along with Roche being the other manufacturer in this segment.
Source-Medindia
SAM
|
|
More News on: Drug Toxicity, Signature Drug Toxicity
 Comment & Contribute
|
|
guest
11/13/2009
wonderful news and a big boost to Indian Pharma sector.Keep it up Cipla
Reply |
Forward
11/12/2009
11/12/2009
|
Medwonders Health Network
- Health News Index
- News Quick Links
| News Categories: |
| » | Schizophrenia Drug Differentiates Cancer Stem Cells into Less Threatening Cells |
| » | Docs Who Seldom Meet Drug Reps Continue to Prescribe Drugs With FDA “Black Box” Warnings |
| » | Revision in Quality Standards for Heparin |
| » | Acne Drug Users At High Risk of Developing Eye Infections |
| » | Patients Who Take Antidepressants When in ICU More Likely to Die |
| More Drug News | |
|
